- Home
- XPRO vs IOVA Comparison
XPRO vs IOVA Comparison
Compare XPRO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- IOVA
- Stock Information
- Founded
- XPRO 1938
- IOVA 2007
- Country
- XPRO United States
- IOVA United States
- Employees
- XPRO N/A
- IOVA N/A
- Industry
- XPRO Oilfield Services/Equipment
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPRO Energy
- IOVA Health Care
- Exchange
- XPRO Nasdaq
- IOVA Nasdaq
- Market Cap
- XPRO 935.2M
- IOVA 1.0B
- IPO Year
- XPRO 2013
- IOVA N/A
- Fundamental
- Price
- XPRO $8.27
- IOVA $3.17
- Analyst Decision
- XPRO Buy
- IOVA Strong Buy
- Analyst Count
- XPRO 3
- IOVA 9
- Target Price
- XPRO $17.67
- IOVA $18.22
- AVG Volume (30 Days)
- XPRO 1.3M
- IOVA 9.3M
- Earning Date
- XPRO 04-30-2025
- IOVA 05-08-2025
- Dividend Yield
- XPRO N/A
- IOVA N/A
- EPS Growth
- XPRO N/A
- IOVA N/A
- EPS
- XPRO 0.58
- IOVA N/A
- Revenue
- XPRO $1,720,185,000.00
- IOVA $164,070,000.00
- Revenue This Year
- XPRO $1.06
- IOVA $182.20
- Revenue Next Year
- XPRO $4.33
- IOVA $62.10
- P/E Ratio
- XPRO $14.18
- IOVA N/A
- Revenue Growth
- XPRO 10.48
- IOVA 13698.99
- 52 Week Low
- XPRO $6.70
- IOVA $2.70
- 52 Week High
- XPRO $24.50
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- XPRO 41.62
- IOVA 43.38
- Support Level
- XPRO $7.60
- IOVA $3.02
- Resistance Level
- XPRO $8.63
- IOVA $3.73
- Average True Range (ATR)
- XPRO 0.49
- IOVA 0.25
- MACD
- XPRO 0.07
- IOVA 0.01
- Stochastic Oscillator
- XPRO 21.60
- IOVA 25.33
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.